Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.

Company profile
Ticker
SRPT
Exchange
Website
CEO
Douglas Ingram
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ANTIVIRALS INC, AVI BIOPHARMA INC
SEC CIK
Corporate docs
Subsidiaries
Sarepta Securities Corp. • ST International Holdings • Sarepta Therapeutics Three, LLC ...
IRS number
930797222
SRPT stock data
News
RBC Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $182
9 Aug 22
Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications
8 Aug 22
Is Biotech Back? This Analyst Sees 18% Upside Potential In This Bio Play
8 Aug 22
Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts
3 Aug 22
RBC Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $160
3 Aug 22
Press releases
Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases
8 Aug 22
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Jul 22
Thinking about trading options or stock in Sarepta Therapeutics, Apple, General Electric, Microsoft, or Meta Platforms?
29 Jul 22
Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy
29 Jul 22
Sarepta Therapeutics' Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
6 Jul 22
Analyst ratings and price targets
Current price
Average target
$136.67
Low target
$93.00
High target
$182.00
RBC Capital
Maintains
$182.00
Morgan Stanley
Maintains
$100.00
Credit Suisse
Maintains
$93.00
Needham
Maintains
$162.00
Cantor Fitzgerald
Maintains
$128.00
Goldman Sachs
Maintains
$155.00
Investment data
Securities sold
Number of investors
Calendar
2 Aug 22
18 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 887.06M | 887.06M | 887.06M | 887.06M | 887.06M | 887.06M |
Cash burn (monthly) | 118.82M | 68.27M | 76.03M | 41.84M | 22.27M | 26.8M |
Cash used (since last report) | 195.67M | 112.43M | 125.21M | 68.89M | 36.68M | 44.14M |
Cash remaining | 691.39M | 774.63M | 761.86M | 818.17M | 850.39M | 842.92M |
Runway (months of cash) | 5.8 | 11.3 | 10.0 | 19.6 | 38.2 | 31.4 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jun 22 | Michael Andrew Chambers | Common Stock | Grant | Acquire A | No | No | 0 | 4,908 | 0 | 4,908 |
2 Jun 22 | Michael Andrew Chambers | Stock Option Common Stock | Grant | Acquire A | No | No | 72.58 | 8,329 | 604.52K | 8,329 |
2 Jun 22 | Kathryn Jean Boor | Common Stock | Grant | Acquire A | No | No | 0 | 4,908 | 0 | 4,908 |
2 Jun 22 | Kathryn Jean Boor | Stock Option Common Stock | Grant | Acquire A | No | No | 72.58 | 8,329 | 604.52K | 8,329 |
1 Jun 22 | Ryan Edward Brown | Common Stock | Payment of exercise | Dispose F | No | No | 72.67 | 54 | 3.92K | 25,841 |
Institutional ownership, Q2 2022
86.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 319 |
Opened positions | 39 |
Closed positions | 45 |
Increased positions | 92 |
Reduced positions | 129 |
13F shares | Current |
---|---|
Total value | 5.66B |
Total shares | 76.07M |
Total puts | 961.4K |
Total calls | 1.18M |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 8.42M | $631.17M |
JHG Janus Henderson | 7.23M | $542.17M |
BLK Blackrock | 5.61M | $420.35M |
Sands Capital Management | 3.71M | $278.18M |
Capital Ventures International | 3.58M | $194.09M |
Avoro Capital Advisors | 3.39M | $254.11M |
EcoR1 Capital | 2.87M | $215M |
Wellington Management | 2.77M | $207.55M |
STT State Street | 2.32M | $173.64M |
BK Bank Of New York Mellon | 1.99M | $149.24M |
Financial report summary
?Competition
Pfizer • PTC • Biogen • Vertex Pharmaceuticals • Arrowhead Pharmaceuticals • Alexion Pharmaceuticals • Roche • FibroGen • Shire • PTC TherapeuticsContent analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accrual, attrition, Beam, began, built, Carlo, Chief, construction, core, half, Henogen, hypomagnesemia, Italfarmaco, landlord, lattice, letter, Monte, notify, output, pre, reauthorize, reopened, SA, shell, simulation, tenant, Undiscounted, Unvested, withdrew
Removed:
announcing, begun, contractually, delivery, Delta, facilitating, MOMENTUM, narrow, referencing, referred, structured, unconsolidated, uninterpretable
Financial reports
Current reports
8-K
Departure of Directors or Certain Officers
3 Jun 22
8-K
Departure of Directors or Certain Officers
21 Apr 22
8-K
Departure of Directors or Certain Officers
5 Apr 22
8-K
Results of Operations and Financial Condition
10 Jan 22
8-K
Departure of Directors or Certain Officers
17 Nov 21
8-K
Entry into a Material Definitive Agreement
15 Oct 21
8-K
Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful
27 Sep 21
8-K
Submission of Matters to a Vote of Security Holders
3 Jun 21
8-K
Regulation FD Disclosure
18 May 21
8-K
Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing
3 May 21
Registration and prospectus
S-8
Registration of securities for employees
2 Aug 22
S-3ASR
Automatic shelf registration
2 Mar 22
424B5
Prospectus supplement for primary offering
15 Oct 21
424B5
Prospectus supplement for primary offering
12 Oct 21
S-8
Registration of securities for employees
5 Aug 20
D
$400M in equity, sold $400M, 1 investor
28 Feb 20
D
$30.5M in equity, sold $30.5M, 1 investor
25 Nov 19
S-3ASR
Automatic shelf registration
14 Nov 19
S-8
Registration of securities for employees
11 Sep 19
424B5
Prospectus supplement for primary offering
7 Mar 19
Proxies
Other
UPLOAD
Letter from SEC
15 Apr 20
CORRESP
Correspondence with SEC
14 Apr 20
UPLOAD
Letter from SEC
12 Apr 20
CT ORDER
Confidential treatment order
9 Nov 18
CT ORDER
Confidential treatment order
11 Sep 17
CT ORDER
Confidential treatment order
18 Jan 17
CT ORDER
Confidential treatment order
3 Oct 16
EFFECT
Notice of effectiveness
4 May 15
CORRESP
Correspondence with SEC
3 May 15
UPLOAD
Letter from SEC
28 Apr 15
Ownership
4
Sarepta Therapeutics / Kathryn Jean Boor ownership change
6 Jun 22
4
Sarepta Therapeutics / Michael Andrew Chambers ownership change
6 Jun 22
3
Sarepta Therapeutics / Michael Andrew Chambers ownership change
6 Jun 22
3
Sarepta Therapeutics / Kathryn Jean Boor ownership change
6 Jun 22
4
Sarepta Therapeutics / Ryan Edward Brown ownership change
3 Jun 22
4
Sarepta Therapeutics / Stephen Mayo ownership change
9 Mar 22
4
Sarepta Therapeutics / Claude Nicaise ownership change
8 Mar 22
4
Sarepta Therapeutics / MARY ANN GRAY ownership change
8 Mar 22
4
Sarepta Therapeutics / Hans Lennart Rudolf Wigzell ownership change
8 Mar 22
4
Sarepta Therapeutics / M KATHLEEN BEHRENS ownership change
8 Mar 22
Patents
Utility
Exon Skipping Compositions for Treating Muscular Dystrophy
18 Aug 22
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
Utility
Exon Skipping Oligomers for Muscular Dystrophy
11 Aug 22
Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
Utility
Exon skipping oligomer conjugates for muscular dystrophy
26 Jul 22
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
Utility
Exon skipping oligomer conjugates for muscular dystrophy
12 Jul 22
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
Utility
Processes for preparing oligomers
12 Jul 22
Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer).
Transcripts
2022 Q2
Earnings call transcript
2 Aug 22
2022 Q1
Earnings call transcript
5 May 22
2021 Q4
Earnings call transcript
2 Mar 22
2021 Q3
Earnings call transcript
4 Nov 21
2021 Q2
Earnings call transcript
5 Aug 21
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
2 Mar 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
6 May 20
Reddit threads
Thoughts on SOFI stock as a long term hold? Predictions 5,10,20+ yrs down the road?
11 Aug 22
Daily Discussion Thread - August 2nd, 2022
2 Aug 22
Daily Discussion Thread - August 1st, 2022
1 Aug 22
Daily Plays July 29, 2022
29 Jul 22
Pre-market summary - June 24th
24 Jun 22
Daily Discussion Thread - May 4th, 2022
4 May 22
Daily Discussion Thread - May 3rd, 2022
3 May 22
Daily Discussion Thread - May 2nd, 2022
2 May 22
Daily Discussion Thread - March 1st, 2022
1 Mar 22
Daily Discussion Thread - February 28th, 2022
28 Feb 22